Pfizer Gains New Commercial Drug Orgovyx In Deal With Myovant
Deal Brings Pfizer Another Prostate Cancer Offering
Executive Summary
Myovant's Orgovyx was just approved by the US FDA for prostate cancer and could be approved soon for two women's health indications.
You may also be interested in...
Myovant/Pfizer Launch Myfembree With An Emphasis On Building Uterine Fibroid Awareness
Myovant CEO David Marek talked to Scrip about why the companies believe patients and physicians will choose Myfembree over AbbVie's Oriahnn.
Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020
Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.
Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020
Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.